68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Inclusion Criteria:

• Signed informed consent

• Subjects of either sex, aged ≥18 years

• Histologically and/or clinically confirmed and/or suspected NET and/or A diagnosticimaging study including but not limited to CT or MRI or FDG PET/CT, NaF PET/CT, bonescan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks ofdosing day

• Recent Blood test results (within 2-4 weeks predose) as WBC: ≥2 x 109/L,Haemoglobin: ≥8.0 g/dL, Platelets: ≥50 x 109/L, ALT, AST, AP:≤ 5 times ULN [ ULN forALT, AST and AP is 70, 20 and 20 Units/I respectively], Bilirubin: ≤3 times ULN [ULNfor total bilirubin is 1.3mg/dL]

• Serum creatinine: Serum creatinine: <170 μmol/L

• egative pregnancy test in women capable of child-bearing

Exclusion Criteria:

• Known hypersensitivity to DOTA, to 68Gallium, to Octreotate or to any of theexcipients of 68Ga-DOTATATE

• Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is onSandostatin® LAR a wash-out phase of 28 days is required before the injection of thestudy drug

• Pregnant or breast-feeding women

• Current somatic or psychiatric disease/condition that may interfere with theobjectives and assessments of the study